Trade

with

Alexion Pharmaceuticals Inc
(NASDAQ: ALXN)
AdChoices
190.29
+4.37
+2.35%
After Hours :
190.29
0.00
0.00%

Open

185.01

Previous Close

185.92

Volume (Avg)

1.81M (1.20M)

Day's Range

185.01-190.85

52Wk Range

113.14-190.85

Market Cap.

37.64B

Dividend Rate ( Yield )

-

Beta

0.68

Shares Outstanding

197.81M

P/E Ratio (EPS)

96.15 (1.99)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 1.55B

    • Net Income

    • 252.90M

    • Market Cap.

    • 37.64B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 20.85

    • PEG (Price/Earnings Growth) Ratio

    • 1.44

    • Beta

    • 0.68

    • Forward P/E

    • 34.48

    • Price/Sales

    • 19.96

    • Price/Book Value

    • 13.05

    • Price/Cash flow

    • 81.97

      • EBITDA

      • 559.07M

      • Return on Capital %

      • 12.58

      • Return on Equity %

      • 15.73

      • Return on Assets %

      • 12.58

      • Book Value/Share

      • 14.57

      • Shares Outstanding

      • 197.81M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 216.50

        • Credit Rating

        • -

        • Analysts

        • 6

        • EPS Estimate

        • 4.97

        • Cashflow Estimate

        • 5.69

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 38.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -0.80

          • 17.04

          • Net Income

            Q/Q (last year)

          • 73.60

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 43.04

          • 63.43

          • Net Income

            5-Year Annual Average

          • 50.10

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 90.87

            • 82.75

            • Pre-Tax Margin

            • 36.58

            • 39.38

            • Net Profit Margin

            • 20.85

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 88.40

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 29.50

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 31.10

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.03

              • 0.76

              • Current Ratio

              • 5.61

              • 2.92

              • Quick Ratio

              • 4.87

              • 2.35

              • Interest Coverage

              • 192.87

              • 38.02

              • Leverage Ratio

              • 1.23

              • 2.21

              • Book Value/Share

              • 14.57

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 87.72

                • 217.39

                • P/E Ratio 5-Year High

                • 93.27

                • 634.30

                • P/E Ratio 5-Year Low

                • 10.81

                • 124.82

                • Price/Sales Ratio

                • 18.32

                • 9.52

                • Price/Book Value

                • 11.98

                • 8.61

                • Price/Cash Flow Ratio

                • 81.97

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • 15.73

                        (24.30)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • 12.58

                        (18.70)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • 14.99

                        (22.00)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • 225.84k

                      • 117.08k

                      • Inventory Turnover

                      • 1.36

                      • 1.48

                      • Asset Turnover

                      • 0.60

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      528.01M
                      Operating Margin
                      34.04
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      81.97
                      Ownership

                      Institutional Ownership

                      97.59%

                      Top 10 Institutions

                      54.09%

                      Mutual Fund Ownership

                      66.17%

                      Float

                      77.43%

                      5% / Insider Ownership

                      1.07%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • VA CollegeAmerica Growth Fund of America

                      •  

                        9,006,061

                      • 0.00

                      • 4.55

                      • VA CollegeAmerica AMCAP

                      •  

                        4,648,035

                      • 0.22

                      • 2.35

                      • Fidelity® Growth Company Fund

                      •  

                        3,427,360

                      • -0.93

                      • 1.73

                      • Vanguard Total Stock Mkt Idx

                      •  

                        3,229,307

                      • 0.73

                      • 1.63

                      • VA CollegeAmerica Invmt Co of America

                      •  

                        3,207,000

                      • 0.00

                      • 1.62

                      • VA CollegeAmerica Cap World Gr and Inc

                      •  

                        2,974,400

                      • 0.00

                      • 1.50

                      • T. Rowe Price Health Sciences Fund

                      •  

                        2,831,800

                      • -0.29

                      • 1.43

                      • T. Rowe Price Growth Stock Fund

                      •  

                        2,803,500

                      • 19.50

                      • 1.42

                      • T. Rowe Price Blue Chip Growth Fund

                      •  

                        2,464,500

                      • 19.46

                      • 1.25

                      • Harbor Capital Appreciation Fund

                      •  

                        2,414,006

                      • 2.78

                      • 1.22

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Capital Research Global Investors

                      •  

                        24,230,065

                      • +3.17%

                      • 12.24

                      • Fidelity Management and Research Company

                      •  

                        17,649,430

                      • -14.47%

                      • 8.92

                      • T. Rowe Price Associates, Inc.

                      •  

                        17,303,461

                      • +11.82%

                      • 8.74

                      • Vanguard Group, Inc.

                      •  

                        10,085,631

                      • +1.91%

                      • 5.10

                      • Jennison Associates LLC

                      •  

                        8,148,246

                      • -2.78%

                      • 4.12

                      • State Street Corp

                      •  

                        7,908,024

                      • +1.31%

                      • 4.00

                      • BlackRock Fund Advisors

                      •  

                        5,898,422

                      • -2.38%

                      • 2.98

                      • J.P. Morgan Investment Management Inc.

                      •  

                        5,833,718

                      • -3.13%

                      • 2.95

                      • Sands Capital Management, LLC

                      •  

                        5,279,782

                      • +0.22%

                      • 2.67

                      • Wells Capital Management Inc.

                      •  

                        4,687,051

                      • -14.44%

                      • 2.37

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Aggressive Growth

                      Style

                      Large Growth

                      Alexion Pharmaceuticals Inc is a Delaware based company, incorporated in 1992. The Company is a biopharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-tra...morensforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company is also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement...more activation is the underlying mechanism. Soliris is designed to inhibit a specific aspect of the complement component of the immune system and thereby treat inflammation associated with chronic disorders in the therapeutic areas of hematology, nephrology, transplant rejection, neurology and ophthalmology. The Company competes with large pharmaceutical companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations.lessless

                      Key People

                      Dr. Leonard Bell,M.D.

                      CEO/Director/Founder/Treasurer/Chairman of the Board

                      Stephen P. Squinto,PhD

                      Executive VP/Founder/Other Executive Officer

                      Vikas Sinha

                      CFO/Executive VP

                      Clare Carmichael

                      Other Executive Officer/Executive VP

                      Martin Mackay

                      Executive VP/Other Corporate Officer

                      • Alexion Pharmaceuticals Inc

                      • 352 Knotter Drive

                      • Cheshire, CT 06410

                      • USA.Map

                      • Phone: +1 203 272-2596

                      • Fax: +1 203 271-8198

                      • alexionpharm.com

                      Incorporated

                      1992

                      Employees

                      1,774

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: